{
    "root": "efb9b587-a68d-4c3e-a0e1-7e5caac736c3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Bupropion Hydrochloride",
    "value": "20250206",
    "ingredients": [
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W"
        },
        {
            "name": "DIBUTYL SEBACATE",
            "code": "4W5IH7FLNY"
        },
        {
            "name": "ETHYLCELLULOSES",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "GLYCERYL BEHENATE/EICOSADIOATE",
            "code": "73CJJ317SR"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED",
            "code": "2165RE0K14"
        },
        {
            "name": "METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SILICA DIMETHYL SILYLATE",
            "code": "EU2PSP0G0W"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        }
    ],
    "indications": "bupropion hydrochloride extended-release tablet ( xl ) aminoketone antidepressant , indicated : treatment major depressive disorder ( mdd ) ( 1.1 ) prevention seasonal affective disorder ( sad ) ( 1.2 )",
    "contraindications": "general : increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) periodically reassess dose need maintenance treatment . ( 2.2 ) major depressive disorder starting dose : 150 mg daily . usual target dose : 300 mg daily ( 2.2 ) 4 days , may increase dose 300 mg daily . ( 2.2 ) seasonal affective disorder initiate treatment autumn prior onset seasonal depressive symptoms . ( 2.3 ) starting dose : 150 mg daily . usual target dose : 300 mg daily . ( 2.3 ) one week , may increase dose 300 mg daily . ( 2.3 ) continue treatment winter season . ( 2.3 ) hepatic impairment moderate severe hepatic impairment : 150 mg every day ( 2.6 ) mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.6 , 8.7 ) renal impairment consider reducing dose and/or frequency dosing . ( 2.7 , 8.6 )",
    "warningsAndPrecautions": "caption : ndc strength quantity description 68180-319-06 150 mg bottles 30 's off-white pale yellow , round , biconvex , coated tablets imprinted `` l015 `` black ink one side plain side 68180-319-09 150 mg bottles 90 's off-white pale yellow , round , biconvex , coated tablets imprinted `` l015 `` black ink one side plain side 68180-319-02 150 mg bottles 500 's off-white pale yellow , round , biconvex , coated tablets imprinted `` l015 `` black ink one side plain side 68180-320-06 300 mg bottles 30 's off-white pale yellow , round , biconvex , coated tablets imprinted `` l016 `` black ink one side plain side 68180-320-09 300 mg bottles 90 's off-white pale yellow , round , biconvex , coated tablets imprinted `` l016 `` black ink one side plain side 68180-320-02 300 mg bottles 500 's off-white pale yellow , round , biconvex , coated tablets imprinted `` l016 `` black ink one side plain side store 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . bupropion hydrochloride extended-release tablets usp ( xl ) may odor .",
    "adverseReactions": "seizure disorder . ( 4 , 5.3 ) current prior diagnosis bulimia anorexia nervosa ( 4 , 5.3 ) abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs . ( 4 , 5.3 ) monoamine oxidase inhibitors ( maois ) : maois intended treat psychiatric disorders bupropion hydrochloride extended-release tablets ( xl ) within 14 days stopping treatment bupropion hydrochloride extended-release tablets ( xl ) . bupropion hydrochloride extended-release tablets ( xl ) within 14 days stopping maoi intended treat psychiatric disorders . addition , start bupropion hydrochloride extended-release tablets ( xl ) patient treated linezolid intravenous methylene blue . ( 4 , 7.6 ) known hypersensitivity bupropion ingredients bupropion hydrochloride extended-release tablets ( xl ) ( 4 , 5.8 )",
    "indications_original": "Bupropion hydrochloride extended-release tablet (XL) is an aminoketone antidepressant, indicated for: treatment of major depressive disorder (MDD)      ( 1.1 ) prevention of seasonal affective disorder (SAD)      ( 1.2 )",
    "contraindications_original": "General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) Periodically reassess the dose and need for maintenance treatment. ( 2.2 ) Major Depressive Disorder Starting dose: 150 mg once daily. Usual      target dose: 300 mg once daily ( 2.2 ) After 4 days, may increase the dose to      300 mg once daily. ( 2.2 ) Seasonal Affective Disorder Initiate treatment in the autumn prior to      onset of seasonal depressive symptoms. ( 2.3 ) Starting dose: 150 mg once daily. Usual      target dose: 300 mg once daily. ( 2.3 ) After one week, may increase the dose to      300 mg once daily. ( 2.3 ) Continue treatment through the winter      season. ( 2.3 ) Hepatic Impairment Moderate to severe hepatic impairment:      150 mg every other day ( 2.6 ) Mild hepatic impairment: Consider      reducing the dose and/or frequency of dosing. ( 2.6 , 8.7 ) Renal Impairment Consider reducing the dose and/or      frequency of dosing. ( 2.7 , 8.6 )",
    "warningsAndPrecautions_original": "Caption:  NDC\n                              \n                           \n                           \n                               Strength\n                              \n                           \n                           \n                               Quantity\n                              \n                           \n                           \n                               Description\n                              \n                           \n                        \n                        \n                            68180-319-06\n                           \n                            150 mg\n                           \n                            Bottles of 30's\n                           \n                            off-white to pale yellow, round, biconvex, coated tablets imprinted with \"L015\" in black ink on one side and plain on the other side\n                           \n                        \n                        \n                            68180-319-09\n                           \n                            150 mg\n                           \n                            Bottles of 90's\n                           \n                            off-white to pale yellow, round, biconvex, coated tablets imprinted with \"L015\" in black ink on one side and plain on the other side\n                           \n                        \n                        \n                            68180-319-02\n                           \n                            150 mg\n                           \n                            Bottles of 500's\n                           \n                            off-white to pale yellow, round, biconvex, coated tablets imprinted with \"L015\" in black ink on one side and plain on the other side\n                           \n                        \n                        \n                            68180-320-06\n                           \n                            300 mg\n                           \n                            Bottles of 30's\n                           \n                            off-white to pale yellow, round, biconvex, coated tablets imprinted with \"L016\" in black ink on one side and plain on the other side\n                           \n                        \n                        \n                            68180-320-09\n                           \n                            300 mg\n                           \n                            Bottles of 90's\n                           \n                            off-white to pale yellow, round, biconvex, coated tablets imprinted with \"L016\" in black ink on one side and plain on the other side\n                           \n                        \n                        \n                            68180-320-02\n                           \n                            300 mg\n                           \n                            Bottles of 500's\n                           \n                            off-white to pale yellow, round, biconvex, coated tablets imprinted with \"L016\" in black ink on one side and plain on the other side\n                           \n                        \n                     \n                  \n                  \n                     Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Bupropion hydrochloride extended-release tablets USP (XL) may have an odor.",
    "adverseReactions_original": "Seizure disorder. ( 4 , 5.3 ) Current or prior diagnosis of bulimia or      anorexia nervosa ( 4 , 5.3 ) Abrupt discontinuation of alcohol,      benzodiazepines, barbiturates, antiepileptic drugs. ( 4 , 5.3 ) Monoamine Oxidase Inhibitors (MAOIs): Do      not use MAOIs intended to treat psychiatric disorders with bupropion      hydrochloride extended-release tablets (XL) or within 14      days of stopping treatment with bupropion hydrochloride extended-release tablets (XL). Do not      use bupropion hydrochloride extended-release tablets (XL) within 14 days of stopping an MAOI intended to treat      psychiatric disorders. In addition, do not start bupropion      hydrochloride extended-release tablets (XL) in a patient      who is being treated with linezolid or intravenous methylene blue. ( 4 , 7.6 ) Known hypersensitivity to bupropion or      other ingredients of bupropion hydrochloride extended-release      tablets (XL) ( 4 , 5.8 )"
}